Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New score could help guide Late-Stage breast cancer treatment decisions

NCT ID NCT01574170

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to develop and validate a scoring system to identify which patients with metastatic breast cancer are likely to live longer with third-line chemotherapy. Researchers will collect clinical, histological, and biological data from 267 women starting a third line of treatment. The goal is to create a tool that helps doctors and patients make more informed decisions about continuing chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which patients with metastatic breast cancer are most likely to benefit from third-line chemotherapy, avoiding unnecessary treatments.
What could go wrong
This is a prognostic tool study, not a treatment trial. The score may not be accurate enough to change practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

267 people

The number who actually took part.

Started

Jun 2012

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women of more than 18 years old 2. WHO 0-4 3. Metastatic breast cancer 4. Progression after two lines of chemotherapy with treatment decision by investigator to start a third-line chemotherapy 5. Evaluable disease 6. Histology: breast carcinoma whatever the histological type, grade, hormone receptor expression and HER-2 7. Patient able to complete the EORTC PAL 15 Questionnaire 8. Patient member in a national insurance scheme 9. Informed consent obtained and signed by the patient Exclusion Criteria: 1. History of other (s) cancer (s) potentially metastatic (s) 2. Woman participating in a third line chemotherapy clinical trial 3. Pregnant women or nursing mothers can not participate in the study 4. Patient under legal guardianship 5. Patient unable to undergo medical test for various reasons including social or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer starting A third line chemotherapy

Contacts and locations

Locations

  • C.M.C.O. Claude Bernard

    Albi, 81000, France

  • CHRU Brest

    Brest, 26609, France

  • CHU Jean Minjoz

    Besançon, 25030, France

  • CHU Rangueil

    Toulouse, 31000, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre Georges François Leclerc

    Dijon, 21079, France

  • Centre Hospitalier Intercommunal de Castres-Mazamet

    Castres, 81108, France

  • Centre Hospitalier Jean Rougier

    Cahors, 46005, France

  • Centre Hospitalier de Rodez

    Rodez, 12000, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Centre d'Oncologie et de Radiothérapie du Parc

    Dijon, 21000, France

  • Clinique La Croix du Sud

    Quint-Fonsegrives, 31130, France

  • Institut Claudius Regaud

    Toulouse, 31052, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

  • Institut de Cancérologie de l'Ouest Paul Papin

    Angers, 49933, France

  • Polyclinique de l'Ormeau

    Tarbes, 65000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.